Compass Therapeutics (CMPX) Share-based Compensation (2019 - 2026)

Compass Therapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 101.79% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $10.9 million (up 20.46% YoY), while the FY2025 annual figure was $8.4 million, down 2.24% from the prior year.
• Share-based Compensation came in at $5.1 million for Q1 2026 at Compass Therapeutics, up from $1.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $5.1 million in Q1 2026 to a low of $1.0 million in Q4 2022.
• A 5-year average of $2.0 million and a median of $1.6 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation slumped 43.68% in 2025 and soared 101.79% in 2026, its largest moves.
• Compass Therapeutics' Share-based Compensation stood at $1.0 million in 2022, then surged by 56.1% to $1.6 million in 2023, then jumped by 39.88% to $2.2 million in 2024, then slipped by 18.45% to $1.8 million in 2025, then jumped by 177.97% to $5.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $5.1 million, $1.8 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison